CUREVAC
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. mRNA programs include novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases (RNActive), molecular therapies designed to trigger the body’s own production of therapeutic proteins (RNArt), and RNA encoded antibodies (RNAntibody). Its most advanced product candidate, CV9104, is being developed in Phase IIb for the treatment of prostate cancer.
CUREVAC
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2000-01-01
Address:
Tübingen, Baden-Wurttemberg, Germany
Country:
Germany
Website Url:
http://www.curevac.com
Total Employee:
251+
Status:
Active
Contact:
+49707198830
Email Addresses:
[email protected]
Total Funding:
1.85 B USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-06-08 | Frame Cancer Therapeutics | Frame Cancer Therapeutics acquired by CureVac | 32 M EUR |
Investors List
German Federal Ministry of Education and Research (BMBF)
German Federal Ministry of Education and Research (BMBF) investment in Grant - CureVac
Qatar Investment Authority
Qatar Investment Authority investment in Venture Round - CureVac
GlaxoSmithKline
GlaxoSmithKline investment in Corporate Round - CureVac
European Investment Bank
European Investment Bank investment in Debt Financing - CureVac
KfW
KfW investment in Venture Round - CureVac
LBBW Asset Management
LBBW Asset Management investment in Series F - CureVac
Baden-Württembergische Versorgungsanstalt für Ärzte
Baden-Württembergische Versorgungsanstalt für Ärzte investment in Series F - CureVac
Landeskreditbank Baden-Württemberg
Landeskreditbank Baden-Württemberg investment in Series F - CureVac
Baillie Gifford
Baillie Gifford investment in Series F - CureVac
Chartwave
Chartwave investment in Series F - CureVac
Key Employee Changes
| Date | New article |
|---|---|
| 2020-08-04 | Curevac names Franz-Werner Haas as CEO |
Official Site Inspections
http://www.curevac.com Semrush global rank: 241.55 K Semrush visits lastest month: 291.99 K
- Host name: dedi3042.your-server.de
- IP address: 188.40.29.42
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "CureVac"
About Us - CureVac
With a single discovery, CureVac opened the world up to the potential of mRNA to treat diseases and create vaccines. Officially founded in 2000, CureVac is … See details»
CureVac - Wikipedia
CureVac N.V. is a German biopharmaceutical company. It develops therapies based on messenger RNA (mRNA). Headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac has had approximately 375 employees since May 2018. See details»
Overview - CureVac
Jun 4, 2025 Our path towards a new class of safe and effective therapeutics started in 2000, with the unexpected discovery by CureVac founder Ingmar … See details»
CureVac Initiates Strategic Restructuring to Align …
Jul 3, 2024 CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative … See details»
CureVac - Crunchbase Company Profile & Funding
CureVac develops messenger RNA (mRNA) technology for a variety of medical applications. The company focuses on creating innovative therapies aimed at … See details»
News - CureVac
Apr 11, 2025 CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous … See details»
CureVac - AnnualReports.com
CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In … See details»
CureVac - Bill & Melinda Gates Foundation
CureVac is accelerating vaccine technology development, getting lifesaving and low-cost vaccines to people who need them most. Website. Domain ... We are a nonprofit organization fighting … See details»
CureVac - Org Chart, Teams, Culture & Jobs - The Org
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and … See details»
☑️CureVac — Consulting Organization from Germany
CureVac — Consulting Organization from Germany with 1001-5000 employees, has experience with European Commission Directorate-General for International Partnerships (EuropeAid … See details»
BioNTech Announces Strategic Transaction to Acquire CureVac in …
Jun 12, 2025 BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into a definitive Purchase Agreement … See details»
CureVac (LON:0A9E) Company Profile & Description - Stock Analysis
Jun 13, 2025 CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company’s … See details»
CureVac - Simple English Wikipedia, the free encyclopedia
CureVac N.V. is a German biopharmaceutical company that creates therapies based on messenger RNA (mRNA). It is headquartered in Tübingen, Germany.The company was … See details»
BioNTech acquires CureVac for $1.25 billion in mRNA deal
BioNTech has announced a $1.25 billion all-stock acquisition of CureVac, uniting two pioneers in mRNA science under one organization. The deal, expected to close later this year, will see … See details»
BioNTech CureVac Acquisition Boosts Cancer Drug Pipeline
Jun 13, 2025 In a bold step toward expanding its mRNA research and cancer treatment capabilities, BioNTech SE has announced its decision to acquire CureVac N.V. for … See details»
GSK goes all-in on CureVac’s mRNA vaccines | pharmaphorum
5 days ago GSK agrees €1.4bn deal to take full control of CureVac's mRNA vaccines for flu and COVID-19, as CureVac slashes staff and pivots to oncology. See details»
CureVac - Contacts, Employees, Board Members, Advisors & Alumni
CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. ... Experience the new Crunchbase, powered by AI . … See details»
BioNTech to Acquire CureVac in Strategic Move to Advance mRNA …
Jun 12, 2025 BioNTech to acquire CureVac for $1.25 billion in an all-stock deal to enhance mRNA cancer therapies development. Quiver AI Summary. BioNTech has announced its … See details»
BioNTech takes over CureVac in $1.25 billion all-stock deal among …
Jun 12, 2025 German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new … See details»
CureVac - Funding, Financials, Valuation & Investors - Crunchbase
CureVac is registered under the ticker NASDAQ:CVAC . Their stock opened with $16.00 in its Aug 14, 2020 IPO. CureVac is funded by 16 investors. German Federal Ministry of Education … See details»